[go: up one dir, main page]

ZA200200085B - Methods of treating and/or suppressing weight gain. - Google Patents

Methods of treating and/or suppressing weight gain.

Info

Publication number
ZA200200085B
ZA200200085B ZA200200085A ZA200200085A ZA200200085B ZA 200200085 B ZA200200085 B ZA 200200085B ZA 200200085 A ZA200200085 A ZA 200200085A ZA 200200085 A ZA200200085 A ZA 200200085A ZA 200200085 B ZA200200085 B ZA 200200085B
Authority
ZA
South Africa
Prior art keywords
treating
methods
weight gain
suppressing weight
suppressing
Prior art date
Application number
ZA200200085A
Other languages
English (en)
Inventor
Fernand Labrie
Yves Deshaies
Denis Richard
Celine Martel
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of ZA200200085B publication Critical patent/ZA200200085B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
ZA200200085A 1999-07-06 2002-01-04 Methods of treating and/or suppressing weight gain. ZA200200085B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14240799P 1999-07-06 1999-07-06

Publications (1)

Publication Number Publication Date
ZA200200085B true ZA200200085B (en) 2003-06-25

Family

ID=22499734

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200200085A ZA200200085B (en) 1999-07-06 2002-01-04 Methods of treating and/or suppressing weight gain.

Country Status (25)

Country Link
US (2) US6710059B1 (fr)
EP (1) EP1196163B1 (fr)
JP (1) JP4790178B2 (fr)
KR (1) KR101141763B1 (fr)
CN (1) CN1390126B (fr)
AR (1) AR034091A1 (fr)
AT (1) ATE447947T1 (fr)
AU (3) AU5957500A (fr)
BR (1) BR0012354A (fr)
CA (1) CA2376158C (fr)
DE (1) DE60043305D1 (fr)
DK (1) DK1196163T3 (fr)
HK (1) HK1046240B (fr)
HU (1) HU230543B1 (fr)
IL (2) IL147485A0 (fr)
MX (1) MX270786B (fr)
MY (1) MY134574A (fr)
NO (1) NO329614B1 (fr)
NZ (1) NZ516453A (fr)
PL (1) PL208972B1 (fr)
RU (3) RU2327461C2 (fr)
TR (2) TR200403328T2 (fr)
TW (1) TWI359015B (fr)
WO (1) WO2001001969A2 (fr)
ZA (1) ZA200200085B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) * 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US6560217B1 (en) 1999-02-25 2003-05-06 3Com Corporation Virtual home agent service using software-replicated home agents
EP1196163B1 (fr) * 1999-07-06 2009-11-11 Endorecherche Inc. Compositions pharmaceutiques pour le traitement de la resistance a l'insuline
WO2001026651A2 (fr) * 1999-10-14 2001-04-19 Endorecherche, Inc. Modulateurs selectifs des recepteurs oestrogeniques pour traiter l'hypertension, des maladies cardio-vasculaires et la resistance a l'insuline ou reduire le risque de contracter ces maladies
RU2342145C2 (ru) * 2000-01-28 2008-12-27 Андорешерш, Инк. Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
MXPA04002249A (es) 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.
CA2478183C (fr) 2002-03-12 2010-02-16 Merck & Co. Inc. Amides substitues
WO2004054573A1 (fr) * 2002-12-13 2004-07-01 N.V. Nutricia Methode et composition permettant d'inhiber la digestion des glucides
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
HUE025651T2 (en) * 2004-10-20 2016-04-28 Endorecherche Inc Sex Steroid precursor in combination with a selective estrogen receptor modulator to prevent and treat vaginal atrophy in postmenopausal women
US20060234993A1 (en) * 2005-04-13 2006-10-19 Eric Marchewitz Use of androstane derivatives for enhancing physical performance
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
BRPI0612586A2 (pt) * 2005-06-29 2010-11-23 Wyeth Corp formulações de estrogênios conjugados e bazedoxifeno
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2615452C (fr) 2005-07-15 2015-03-31 Micell Technologies, Inc. Enrobages polymeres renfermant de la poudre de medicament a morphologie commandee
WO2007127363A2 (fr) 2006-04-26 2007-11-08 Micell Technologies, Inc. Revêtements contenant plusieurs médicaments
WO2008042909A2 (fr) 2006-10-02 2008-04-10 Micell Technologies Inc. Sutures chirurgicales ayant une résistance accrue
JP5336382B2 (ja) * 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (fr) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents comportant des couches biodegradables
BRPI0810370A2 (pt) * 2007-04-17 2014-10-29 Micell Technologies Inc Stent revestido, e, método para preparar um stent
EP2170418B1 (fr) * 2007-05-25 2016-03-16 Micell Technologies, Inc. Films de polymères pour le revêtement des dispositifs médicaux
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
CN102083397B (zh) 2008-04-17 2013-12-25 米歇尔技术公司 具有生物可吸收层的支架
CA2730995C (fr) * 2008-07-17 2016-11-22 Micell Technologies, Inc. Dispositif medical d'administration de medicament
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
WO2010111232A2 (fr) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Dispositif médical d'administration de médicament
WO2010111196A2 (fr) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Endoprothèses périphériques dotées de couches
EP2411440B1 (fr) * 2009-03-23 2018-01-17 Micell Technologies, Inc. Polymères biodégradables améliorés
JP2012522589A (ja) * 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
EP3366326A1 (fr) 2009-04-17 2018-08-29 Micell Technologies, Inc. Endoprothèses vasculaires ayant une élution contrôlée
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP2455082A4 (fr) * 2009-07-16 2012-12-19 Univ Kyushu Nat Univ Corp Inducteur de cellule productrice d'insuline, activateur de l'absorption de glucose et agent thérapeutique pour le diabète ou des complications du diabète
EP2453834A4 (fr) 2009-07-16 2014-04-16 Micell Technologies Inc Dispositif médical distributeur de médicament
EP2531140B1 (fr) 2010-02-02 2017-11-01 Micell Technologies, Inc. Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
KR20160088947A (ko) 2010-06-16 2016-07-26 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
EP2593039B1 (fr) 2010-07-16 2022-11-30 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CA2857057A1 (fr) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Modulateurs fluores des recepteurs d'ƒstrogenes et leurs utilisations
SG11201402564QA (en) 2011-12-16 2014-09-26 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
CA2905419C (fr) 2013-03-12 2020-04-28 Micell Technologies, Inc. Implants biomedicaux bioabsorbables
KR102079613B1 (ko) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3395809A4 (fr) * 2015-12-22 2019-06-19 Jiangsu Hengrui Medicine Co. Ltd. Dérivé de benzopipéridine, son procédé de préparation et son utilisation médicale
US20180207177A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2)
CN114315851B (zh) * 2022-01-03 2023-10-24 安徽大学绿色产业创新研究院 一种光甘草定药物中间体的合成方法
JP7440838B1 (ja) 2023-07-06 2024-02-29 株式会社インタートレードヘルスケア 卵巣機能欠落生体の内臓脂肪蓄積抑制飲食品、及び卵巣機能欠落生体の内臓脂肪蓄積抑制薬

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504119B1 (fr) * 1981-04-17 1985-09-20 Aury Jean Pierre Beton isolant ainsi que son procede de fabrication
DE3117979A1 (de) * 1981-05-07 1983-01-20 Hoechst Ag, 6000 Frankfurt Neue(delta)1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
ZA931601B (en) * 1992-03-06 1993-10-05 Squibb & Sons Inc Microsomal triglyceride transfer protein
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW275584B (fr) * 1993-06-24 1996-05-11 Fli Lilly And Co
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
RU2098330C1 (ru) * 1996-01-05 1997-12-10 Акционерное общество открытого типа "ХИТОН" Способ подачи и аэрозольного распылиения жидкого активного продукта и устройство для его осуществления
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5843984A (en) * 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
AU8433898A (en) * 1997-07-10 1999-02-08 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for increasing insulin sensitivity
AU757206B2 (en) * 1997-08-15 2003-02-06 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
JP2003525843A (ja) * 1997-10-08 2003-09-02 ジェネシスコスメティックス ライツ アンド ライセンシズ カンパニー リミテッド 脂肪細胞を含む身体部位の引き締めおよび／または縮小
UA66861C2 (uk) 1998-05-15 2004-06-15 Уайт 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
AU771352B2 (en) * 1999-06-18 2004-03-18 Stephen James Cordell Finishing tool
EP1196163B1 (fr) * 1999-07-06 2009-11-11 Endorecherche Inc. Compositions pharmaceutiques pour le traitement de la resistance a l'insuline

Also Published As

Publication number Publication date
WO2001001969A2 (fr) 2001-01-11
DK1196163T3 (da) 2010-03-29
CN1390126A (zh) 2003-01-08
TW200803838A (en) 2008-01-16
NZ516453A (en) 2004-04-30
PL352993A1 (en) 2003-09-22
RU2013148518A (ru) 2015-05-10
EP1196163A2 (fr) 2002-04-17
BR0012354A (pt) 2002-04-02
EP1196163B1 (fr) 2009-11-11
DE60043305D1 (de) 2009-12-24
US8609695B2 (en) 2013-12-17
MY134574A (en) 2007-12-31
KR20020020776A (ko) 2002-03-15
RU2008101793A (ru) 2009-07-27
IL195860A (en) 2013-06-27
HUP0202363A2 (en) 2002-10-28
AR034091A1 (es) 2004-02-04
MX270786B (es) 2009-10-08
JP2003503446A (ja) 2003-01-28
MXPA02000075A (es) 2003-05-23
PL208972B1 (pl) 2011-07-29
TR200403328T2 (tr) 2005-03-21
HK1046240A1 (en) 2003-01-03
NO20020037L (no) 2002-03-04
NO329614B1 (no) 2010-11-22
HUP0202363A3 (en) 2005-02-28
AU2009200258B2 (en) 2012-01-12
TWI359015B (en) 2012-03-01
HK1046240B (en) 2010-09-30
IL147485A0 (en) 2002-08-14
AU2005229713A1 (en) 2005-12-01
RU2636498C2 (ru) 2017-11-23
CN1390126B (zh) 2012-06-13
AU5957500A (en) 2001-01-22
KR101141763B1 (ko) 2012-05-08
AU2009200258A1 (en) 2009-02-26
CA2376158C (fr) 2011-03-15
RU2327461C2 (ru) 2008-06-27
US20040034000A1 (en) 2004-02-19
US6710059B1 (en) 2004-03-23
ATE447947T1 (de) 2009-11-15
TR200502284T2 (tr) 2005-08-22
NO20020037D0 (no) 2002-01-04
RU2519642C2 (ru) 2014-06-20
JP4790178B2 (ja) 2011-10-12
HU230543B1 (hu) 2016-11-28
WO2001001969A3 (fr) 2001-08-02
CA2376158A1 (fr) 2001-01-11

Similar Documents

Publication Publication Date Title
ZA200200085B (en) Methods of treating and/or suppressing weight gain.
PL354102A1 (en) Pyrazolecarboxamide and pyrazolethioamide as fungicide
AU2001249881A1 (en) Method of treating the heart
AU2754201A (en) Method and system for treating cardiac arrest
EP1231887A4 (fr) Methode et composition pour le traitement de cicatrices
AU2495200A (en) Compositions and methods for the treatment of tumor
ZA200202816B (en) Modified plant viruses and methods of use thereof.
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
ZA200108446B (en) Novel method of treatment.
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
IL144561A0 (en) Liposome compositions and methods for treating pests utilizing the same
AU1303301A (en) Body weight gain inhibitors
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
PL342870A1 (en) Wood preserving agents, methods of obtaining them and their application
SG92610A1 (en) The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis
HUP0102995A3 (en) Agents and method for the protective treatment of wood
ZA200101188B (en) DNAzymes and methods for treating restenosis.
GB0122806D0 (en) Organ arrest, protection and preservation
IL145239A0 (en) Treatment of certain cancers associated with weight gain
KR100511819B1 (en) Compositions and Methods for the Treatment of Tumor
GB9920670D0 (en) Stabilisation of peroxidases